These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32731506)

  • 1. Protein Arginine Methyltransferase 5 as a Therapeutic Target for
    Shifteh D; Sapir T; Pahmer M; Haimowitz A; Goel S; Maitra R
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PRMT5-mediated regulation of DKK1 sensitizes colorectal cancer cells to chemotherapy.
    Abumustafa W; Castven D; Becker D; Salih SS; Manzoor S; Zamer BA; Talaat I; Hamad M; Marquardt JU; Muhammad JS
    Cell Signal; 2024 Jul; 119():111166. PubMed ID: 38588876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5-mediated methylation of YBX1 regulates NF-κB activity in colorectal cancer.
    Hartley AV; Wang B; Mundade R; Jiang G; Sun M; Wei H; Sun S; Liu Y; Lu T
    Sci Rep; 2020 Sep; 10(1):15934. PubMed ID: 32985589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
    Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
    Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
    Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
    Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell metabolic profiling of colorectal cancer via
    Ge S; Zhang Q; Tian Y; Hao L; Duan J; Zhang B
    Clin Chim Acta; 2020 Nov; 510():291-297. PubMed ID: 32707041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines
    Ernzen K; Melvin C; Yu L; Phelps C; Niewiesk S; Green PL; Panfil AR
    Front Microbiol; 2023; 14():1101544. PubMed ID: 36819050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on
    Siegman A; Shaykevich A; Chae D; Silverman I; Goel S; Maitra R
    Curr Issues Mol Biol; 2024 Jul; 46(7):7530-7547. PubMed ID: 39057088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
    Jing P; Xie N; Zhu X; Dang H; Gu Z
    J Thorac Dis; 2018 Dec; 10(12):7014-7019. PubMed ID: 30746248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil increases the antitumor activity of 5-FU through inhibiting PRMT5-mediated glycolysis and cell proliferation in colorectal cancer.
    Shen Y; Zhao P; Dong K; Wang J; Li H; Li M; Li R; Chen S; Shen Y; Liu Z; Xie M; Shen P; Zhang J
    Cancer Metab; 2022 Dec; 10(1):22. PubMed ID: 36474242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
    Chen H; Lorton B; Gupta V; Shechter D
    Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
    Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM
    Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein arginine methyltransferase PRMT5 regulates Aβ-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
    Quan X; Yue W; Luo Y; Cao J; Wang H; Wang Y; Lu Z
    J Neurochem; 2015 Sep; 134(5):969-77. PubMed ID: 26086249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue.
    Prabhu L; Martin M; Chen L; Demir Ö; Jin J; Huang X; Motolani A; Sun M; Jiang G; Nakshatri H; Fishel ML; Sun S; Safa A; Amaro RE; Kelley MR; Liu Y; Zhang ZY; Lu T
    Genes Dis; 2023 Jan; 10(1):267-283. PubMed ID: 37013054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.